MVA p53 vaccine - Tara Immuno-Oncology

Drug Profile

MVA p53 vaccine - Tara Immuno-Oncology

Alternative Names: Modified-Vaccinia-Ankara-p53-vaccine; p53-MVA-vaccine; p53MVA vaccine - Tara Immmuno-Oncology

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA)
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Refractory metastatic disease, Second-line therapy or greater) in USA (SC)
  • 18 Apr 2017 City of Hope Medical Center plans a phase II trial for Ovarian cancer (Combination therapy, Second-line therapy or greater, Recurrent) in USA (NCT03113487)
  • 03 Nov 2015 Tara Immuno-Oncology in-licenses p53MVA vaccine from City of Hope National Medical Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top